Table 2.
Gene | Middleton et al. [58] |
Beksac et al. [60] |
Al Omar et al. [61] |
Kim et al. [57] |
Meta-analysis |
||||
---|---|---|---|---|---|---|---|---|---|
Cancer N = 90 | Control N = 100 | Cancer N = 87 | Control N = 154 | Cancer N = 52 | Control N = 70 | Cancer N = 241 | Control N = 159 | P value (ED) | |
2DL1 | 86 | 94 | 77 | 147 | 51 | 70 | 241 | 159 | 0.32 (−) |
2DL2 | 61 | 57 | 68 | 103 | 47 | 55 | 27 | 20 | 0.07 (+) |
2DL3 | 69 | 85 | 48 | 56 | 240 | 159 | 0.99 (+) | ||
2DL4 | 52 | 70 | 241 | 159 | Excluded | ||||
2DL5 | 50 | 52 | 45 | 53 | 107 | 59 | 0.09 (+) | ||
3DL1 | 83 | 91 | 51 | 66 | 229 | 156 | 0.45 (−) | ||
3DL2 | 52 | 70 | 241 | 159 | Excluded | ||||
3DL3 | 50 | 70 | 241 | 159 | Excluded | ||||
2DS1 | 36 | 39 | 40 | 75 | 43 | 25 | 106 | 56 | 0.28 |
2DS2 | 61 | 58 | 54 | 103 | 46 | 50 | 31 | 31 | 0.09 (−) |
2DS3 | 29 | 34 | 34 | 52 | 40 | 40 | 32 | 29 | 0.81 (+) |
2DS4 | 82 | 91 | 51 | 70 | 229 | 156 | 0.41 (−) | ||
2DS5 | 34 | 26 | 35 | 22 | 80 | 33 | 0.0001(+)**** | ||
3DS1 | 34 | 39 | 35 | 76 | 43 | 16 | 99 | 56 | 0.18 (+) |
2DP1 | 52 | 70 | 241 | 159 | Excluded | ||||
3DP1 | 52 | 70 | 241 | 159 | Excluded |
Significance at P < 0.05 level.